top of page
ANGEL2 and Tumor Metabolism
Our work explores how the mitochondrial regulator ANGEL2 drives metabolic stress, immune evasion, and therapy resistance across genitourinary cancers.
​Mitochondrial dysfunction is a defining feature of cancer progression and therapeutic resistance. Our lab investigates the role of the mitochondrial regulator ANGEL2 in shaping metabolic stress responses, oxidative balance, and immune evasion across genitourinary cancers. Through molecular, cellular, and 3D-bioprinted model systems, we aim to define how ANGEL2 influences tumor plasticity and survival under therapeutic pressure. By uncovering the metabolic and immunologic pathways governed by ANGEL2, we seek to identify novel vulnerabilities that can be targeted to overcome resistance and enhance treatment efficacy in muscle-invasive bladder and other GU malignancies.
bottom of page